Avalanche Sample Clauses

Avalanche. From the Effective Date through the Closing Date, AEG, HC, and Avalanche LLC shall comply in all material respects with all conditions and requirements set forth in (i) all applicable Sports Entities' Contracts, (ii) the Organizational Documents applicable to such entities, (iii) any and all applicable NHL agreements and documents or other material Contracts of such entities, (iv) the VCUP, (v) Applicable Law, and (vi) this Agreement. AEG, HC and Avalanche LLC will coordinate with Purchasers the method of funding of the NHL Strike Fund Amount, if any.
Sample 1See All (4)
AutoNDA by SimpleDocs
Avalanche. Figure 16: Network of common cause potentials, where each link represents the fact that an event affects multiple entities concurrently. The network is composed of 54 potentials. We model the fact that two entities are likely to be affected simultaneously by an avalanche if the distance of two entities is less than 9 km. In the figure above, we show the network that summarises such potential common failures. In the next table we provide these potentials. For each link, we detail the two endpoints (from and to). Table 16: Common cause failure potentials with respect to an avalanche. ID From To CCFA1 UA17 UA9 CCFA2 UA18 UA6 CCFA3 UA18 UA11 CCFA4 XX00 XX00 XXXX0 XX00 XX0 CCFA6 UA22 UA7 CCFA7 XX00 XX00 XXXX0 XX00 XX00 CCFA9 XX00 XX00 XXXX00 XX00 XX0 CCFA11 XX0 XX00 XXXX00 XX0 XX0 CCFA13 BS2 UA3 CCFA14 XX0 XX00 XXXX00 XX0 XX0 CCFA16 XX0 XX00 CCFA17 XX0 XX00 CCFA18 XX0 XX0 CCFA19 BS6 XX0 XXXX00 XX0 XX00 CCFA21 XX00 XX00 XXXX00 XX00 XX00 CCFA23 XX00 XX0 CCFA24 BS13 XX00 XXXX00 BS14 XX0 XXXX00 BS14 XX0 XXXX00 BS18 XX00 XXXX00 BS18 XX00 XXXX00 BS19 UA12 CCFA30 XX00 XX00 XXXX00 XX00 XX00 CCFA32 BS21 XX00 XXXX00 BS22 UA5 CCFA34 XX00 XX0 CCFA35 60BS23 UA28 CCFA36 XX00 XX0 CCFA37 BS24 XX0 XXXX00 BS25 UA15 CCFA39 XX00 XX0 XXXX00 XX00 XX00 CCFA41 BS26 XX00 XXXX00 BS28 UA13 CCFA43 XX00 XX0 CCFA44 BS28 XX00 XXXX00 XX00 XX0 XXXX00 XX00 XX00 CCFA47 XX00 XX0 CCFA48 BS29 XX00 XXXX00 BS30 XX0 XXXX00 BS32 XX0 XXXX00 XX00 XX0 XXXX00 XX00 XX00 CCFA53 BS34 XX00 XXXX00 XX00 XX00
Sample 1

Related to Avalanche

  • Development Diligence Novartis shall dedicate commercially reasonable efforts, during each [**] month period, necessary to continue the advancement of Licensed Compounds and Licensed Products with respect to at least one Profile towards the next clinical Development milestone or approval milestone, as described in Sections 7.4.2 or 7.4.3, respectively. If Novartis (itself or through its Affiliates or sublicensees) fails to dedicate commercially reasonable efforts, during any [**] month period, necessary to continue the advancement of Licensed Compounds and Licensed Products with respect to at least one Profile towards such next milestone, then any dispute regarding Novartis’ failure of development diligence with respect to such Profile shall be resolved in accordance with Article 13.

  • Commercial Supply Celgene shall Manufacture and supply all Commercial Supplies.

  • Commercial Diligence Upon execution of this Agreement, Licensee shall diligently proceed with Commercially Diligent Efforts to develop, manufacture, practice, sell and use the Licensed Products in order to make them readily available to the general public as soon as possible on commercially reasonable terms. Licensee shall continue active, diligent Commercially Diligent Efforts for one or more Licensed Product(s) throughout the term of this Agreement (“Actively Commercializing”). In addition, Licensee shall perform at least the following obligations as part of its due diligence activities hereunder:

  • Development 3.3 Within twenty (20) Working Days after the Commencement Date and in accordance with paragraphs 3.10 to 3.12 (Amendment and Revision), the Contractor will prepare and deliver to the Authority for approval the full and final Security Plan which will be based on the draft Security Plan set out in Appendix B.

  • Manufacturing and Supply Genentech shall be responsible for manufacturing and supplying Licensed Products for clinical use and commercial sale in the Genentech Field.

  • Research Analyst Independence The Company acknowledges that the Underwriters’ research analysts and research departments are required to be independent from their respective investment banking divisions and are subject to certain regulations and internal policies, and that such Underwriters’ research analysts may hold views and make statements or investment recommendations and/or publish research reports with respect to the Company and/or the offering that differ from the views of their respective investment banking divisions. The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against the Underwriters with respect to any conflict of interest that may arise from the fact that the views expressed by their independent research analysts and research departments may be different from or inconsistent with the views or advice communicated to the Company by such Underwriters’ investment banking divisions. The Company acknowledges that each of the Underwriters is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short positions in debt or equity securities of the companies that may be the subject of the transactions contemplated by this Agreement.

  • Manufacturing and Marketing Rights The Company has not granted rights to manufacture, produce, assemble, license, market, or sell its products to any other person and is not bound by any agreement that affects the Company's exclusive right to develop, manufacture, assemble, distribute, market, or sell its products.

  • Development Efforts 4.2.1 Hana shall use Commercially Reasonable Efforts to Develop each Product in the Territory (including carrying out its responsibilities under the Development Plan) to:

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!